Statistics on Biotechnology Use  
Business Sector
Biotechnology indicators by branch of activity.
Unidades: Specified in each variable

;Total companies;Services;Industry and Construction;Agriculture;
Number of companies carrying out R&D in Biotechnology;1.444;107;455;883;
% Companies by type of biotechnology used: Genetic Code;30,7;21,5;16,8;38,9;
% Companies by type of biotechnology used: Functional Units;37,6;18,7;33,2;42,1;
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;21,3;15,6;15,1;25,2;
% Companies by type of biotechnology used: Bioprocesses;50,9;47,5;75,7;38,6;
% Companies by type of biotechnology used: Subcellular Organisms;8,1;0,9;6,6;9,7;
% Companies by type of biotechnology used: Bioinformatics;22,6;4,7;10,2;31,2;
% Companies by type of biotechnology used: Nanobiotechnology;9,8;0,9;5,1;13,3;
% Companies by type of biotechnology used: Other;16,9;29,6;9,8;19;
Companies in which biotechnology activities are: Main and/or exclusive;629;20;111;498;
Companies in which biotechnology activities are: A secondary business line;262;17;100;145;
Companies in which biotechnology activities are: A necessary tool for production;553;70;243;240;
% Companies by final application areas of biotechnology use: Human Health;44,3;1,9;24,5;59,6;
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;15,8;17,9;13,2;16,9;
% Companies by final application areas of biotechnology use: Food Products;30,7;30,9;48,3;21,6;
% Companies by final application areas of biotechnology use: Agriculture and Forestry;24,9;65,7;22,2;21,4;
% Companies by final application areas of biotechnology use: Environment;16,9;13,2;17,2;17,2;
% Companies by final application areas of biotechnology use: Industry;12,6;6,3;13;13,1;
R&D personnel in Biotechnology (PP);17.743;1.000;5.585;11.158;
R&D personnel in Biotechnology (PP): Research personnel;9.445;293;2.218;6.934;
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;8.298;708;3.367;4.224;
R&D personnel in Biotechnology (PP). Women;9.907;356;3.102;6.449;
R&D personnel in Biotechnology (PP). Women: Research personnel;5.104;113;1.155;3.836;
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;4.802;243;1.946;2.613;
R&D personnel in Biotechnology (FTE);12.993,4;616,8;3.924,1;8.452,5;
R&D personnel in Biotechnology (FTE): Research personnel;7.069,9;194,7;1.616;5.259,3;
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;5.923,6;422,1;2.308,1;3.193,3;
R&D personnel in Biotechnology (FTE). Women;7.471,8;223,8;2.336,7;4.911,2;
R&D personnel in Biotechnology (FTE). Women: Research personnel;3.870,1;73,4;894;2.902,8;
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;3.601,6;150,5;1.442,8;2.008,4;
Expenditure on internal R&D in Biotechnology (thousands of euros);1.223.801;36.807;437.823;749.171;
1) By type of expenditure: Current expenditure;1.108.189;33.108;406.903;668.179;
1.1) Labour expenditure of research personnel;360.922;9.392;108.070;243.460;
1.2) Labour expenditure of technical and auxiliary personnel;220.540;11.866;91.401;117.272;
1.3) Other current expenditure;526.727;11.849;207.432;307.446;
2) By type of expenditure: Capital expenditure;115.612;3.699;30.921;80.993;
2.1) Land and buildings;16.843;1.812;2.957;12.074;
2.2) Equipment and tools;63.527;1.809;22.909;38.809;
2.3) Acquisition of specific R&D software;3.959;61;841;3.057;
2.4) Other R&D-specific IP products;31.284;17;4.214;27.054;
1.1) By origin of funds: Own funds;860.603;34.837;371.804;453.963;
1.2) By origin of funds: Funds from the Business sector;128.002;84;5.242;122.675;
1.3) By origin of funds: Funds from the Public Administration sector;119.498;1.832;17.353;100.313;
1.4) By origin of funds: Funds from the Higher Education sector;647;0;9;638;
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;12.986;0;19;12.966;
1.6) By origin of funds: Funds from the rest of the world;102.065;54;43.395;58.617;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);123.396;775;74.871;47.750;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;88.985;775;63.502;24.707;
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;34.412;0;11.368;23.043;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;39,8;31,1;28,2;46,8;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;15,3;15,3;18,5;13,6;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;22,3;24,6;20,8;22,8;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;12,1;8,1;11,5;12,9;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;17,1;8,1;12,2;20,7;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;17,8;11;14,6;20,3;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;16;14,9;16,5;15,8;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;41,4;49;39,6;41,5;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;50,2;51,3;50,5;50;
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;20,1;25,4;17,2;20,9;
% Companies with international revenues related to biotechnology activities;22,7;8,1;22,3;24,7;
% Companies representing international revenues related to biotechnology activities;2,1;4,6;1,9;3,5;
% International revenues related to biotechnology activities distributed in: Revenues from the EU;60,6;88,4;63;46,9;
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;39,4;11,6;37;53,1;
% International revenues related to biotechnology activities by classification: International trade in goods and services;87,8;100;88,6;82,7;
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;10,1;0;10,7;8,8;
% International revenues related to biotechnology activities by classification: Subsidies from external sources;1,4;0;0,6;4,9;
% International revenues related to biotechnology activities by classification: Other;0,8;0;0,1;3,6;
Notas:
Data referring to all companies that carry out internal R&D in Biotechnology.
 2) ' .'= numeric data equal to zero not resulting from rounding
 3) FTE: Full-Time Equivalence
Fuente: National Statistics Institute